Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Approved for this indication (1)

• nelarabine

Phase 3 trials (12)

• decitabine
• venetoclax
• haploidentical mononuclear cells
• Filgrastim
• omacetaxine
• cyclophosphamide
• daunorubicin
• vindesine
• cytarabine
• asparagine
• aclarubicin
• dexamethasone

Phase 2 trials (38)

• azacitidine
• tioguanine
• mercaptopurine
• urea
• busulfan
• calaspargase pegol
• diphenhydramine
• prednisone
• naltrexone
• hydrocortisone
• hyaluronidase (human recombinant)
• vincristine
• pegaspargase
• acetaminophen
• ruxolitinib
• Isatuximab
• stem cells
• dasatinib
• Anti-thymocyte Globulin (Rabbit)
• bortezomib
• vorinostat
• anti-cd7 car-pnk cells
• cd45-depleted allogenic peripheral blood stem cell
• methotrexate
• fludarabine
• romidepsin
• daratumumab
• prednisolone
• mitoxantrone
• ranitidine
• +8 more

Phase 1 trials (16)

• allogeneic natural killer cells
• bms-906024
• mk-0752
• doxorubicin
• ezn3042
• cd19 car-t cells
• cd5.car/28zeta car t cells
• mesna
• rituximab
• cd123 car-t cells
• cd7.car/28zeta car t cell
• anti-trbc1 car-t cell therapy
• xmab18968
• senl101
• cd1a-car t
• vgo-cs01p

Other trials (1)

• chia seed

Organization Involved with Phase 3 Indications (9)

• National Cancer Institute (NCI)
• Anhui Medical University
• Changzhou No.2 People's Hospital
• Nanjing University
• Shandong Provincial Hospital
• Soochow University
• Henan Medical University
• Shenzhen University
• The Second People's Hospital of Huai'an

Organization Involved with Phase 2 Indications (68)

• Spectrum Pharmaceuticals
• BioCryst
• Eli Lilly
• Sanofi
• Novartis
• Mundipharma
• PersonGen BioTherapeutics (Suzhou) Co., Ltd.
• National Institutes of Health (NIH)
• Federal Research Institute of Pediatric Hematology, Oncology and Immunology
• Cornell University
• ECOG-ACRIN Cancer Research Group
• Faculdade de Medicina do ABC
• Emory University
• Federal University of Rio Grande do Sul
• University of Washington
• Hospital Nossa Senhora da Conceicao
• Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
• Medical College of Wisconsin
• New York Medical College
• Shenzhen Geno-Immune Medical Institute
• Southwest Oncology Group
• Sichuan University
• Tufts University
• University of Florence
• University of Florida
• University of Palermo
• University of Regensburg
• University of Rochester
• University of Southern California
• University of Toronto
• +38 more

Organization Involved with Phase 1 Indications (13)

• Bristol-Myers Squibb
• Enzon
• Merck
• Baylor University
• Johns Hopkins University
• New York University
• Peking University
• City of Hope National Medical Center
• Methodist Cancer Center, Houston, Texas
• Vasgene Therapeutics, Inc
• L K Whittier Foundation
• Assisi Foundation
• iCell Gene Therapeutics

Organization Involved with Other Experimental Indications (3)

• Hebei Senlang Biotechnology Inc., Ltd.
• Ludaopei Hospital
• Hebei Yanda Ludaopei Hospital